R&D Trends

Corgenix inks contract manufacturing deal with EDP Biotech

Tuesday, July 16, 2013 10:30 AM

Corgenix Medical, a worldwide developer and marketer of diagnostic test kits, has entered into a 10-year contract manufacturing agreement with EDP Biotech, a medical device company focused on the development and commercialization of immunodiagnostic tests for humans.

More... »

Boston-based Alzheimer's disease research highlighted at Alzheimer's Association International Conference 2013

Tuesday, July 16, 2013 09:35 AM

Three studies reported at the Alzheimer's Association International Conference 2013 (AAIC) demonstrate the vitality and diversity of Alzheimer's disease research being conducted in Boston, the host city for this year's conference.

More... »

Catalent, Biota Pharmaceuticals expand alliance

Tuesday, July 16, 2013 09:30 AM

Catalent Pharma Solutions, a global development solutions and advanced drug delivery technologies company, and Biota Pharmaceuticals have allied to develop and provide filling and packaging capabilities to supply clinical trial materials of laninamivir octanoate, a first-in-class, inhaled, long-acting neuraminidase inhibitor being developed by Biota to treat influenza A and B viruses.

More... »

Ipsen, Harvard Medical School to collaborate

Monday, July 15, 2013 10:50 AM

Global pharmaceutical company Ipsen has initiated an R&D collaboration on novel engineered botulinum toxins with Harvard Medical School. Ipsen will fund Harvard research for at least three years to discover, evaluate and develop novel engineered recombinant botulinum toxins for the treatment of neurologic diseases.

More... »

Ipsen acquires Syntaxin

Monday, July 15, 2013 10:48 AM

Global pharmaceutical company Ipsen has acquired Syntaxin, a U.K.-based private life sciences company specialized in botulinum toxin engineering. Ipsen will pay $36.4 million up front, as well as up to $169 million in development and commercial milestones.

More... »

Artes Biotechnology, Bio Farma collaborate on vaccines

Monday, July 15, 2013 10:46 AM

Germany-based biotech Artes and Bio Farma, based in Indonesia, have joined to develop and manufacture vaccine candidates. The collaboration involves Artes’ specialization in cell line and process development, VLP-based vaccines and technology transfer for production processes, and Bio Farma’s experience manufacturing vaccines for the Indonesian domestic and international markets.

More... »

Mitsubishi Tanabe Pharma acquires Medicago in $357 million deal

Friday, July 12, 2013 03:13 PM

Mitsubishi Tanabe Pharma (MTPC) has agreed to acquire Quebec-based Medicago, a biopharmaceutical company focused on developing vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs).

More... »

Accenture launches Accelerated R&D Services

Friday, July 12, 2013 02:05 PM

Accenture, a global management consulting, technology services and outsourcing company, has launched the Accenture Accelerated R&D Services, a business service focused on delivering streamlined and integrated R&D functions to help pharmaceutical companies bring new medications to patients using a more collaborative approach. Accenture is investing more than $200 million to deliver this fully-integrated, technology-enabled global business service.

More... »

China investing billions in bid to catch up with Western pharma

Friday, July 12, 2013 01:55 PM

China's biomedical sector is transforming itself from a manufacturing base to an innovation hub, investing billions of dollars and setting up innovation centers in a bid to catch up with the west by the end of the 12th Five-Year Plan, according to Lux Research, which provides advice and ongoing intelligence for emerging technologies.

More... »

Michael J. Fox Foundation announces research partners

Friday, July 12, 2013 01:50 PM

Research projects from five biopharmaceutical companies in the U.S., Canada and Israel comprise the 2013 first half of The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program. Participants' research projects are presented directly to industry groups that may wish to invest in further development. By connecting industry leaders with those studies ripe for investment, the Foundation aims to drive forward promising research in Parkinson's disease (PD) through the pipeline of drug development and eventually into patients' hands.

More... »